Alzheimer's disease, a progressive neurological disorder, poses significant challenges in treatment. Medications for Alzheimer's primarily aim to manage symptoms rather than cure the disease. Cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine are commonly prescribed to enhance communication among brain cells by preserving acetylcholine, a neurotransmitter critical for memory and learning. Another class of drugs, NMDA receptor antagonists like memantine, regulates glutamate activity to moderate symptoms.
However, these medications only offer temporary relief from cognitive decline and do not halt the disease's progression. They may alleviate symptoms such as memory loss, confusion, and changes in behavior, providing patients and caregivers with improved quality of life in the early to moderate stages of Alzheimer's. Research into new treatments continues to explore novel approaches, but current therapies underscore the need for holistic care strategies that encompass medication, therapy, and support services for both patients and their families.
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Cogs Club: Making a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States